Skip to main content

Table 1 Baseline data

From: Prevalence and risk factors of myocardial and acute kidney injury following radical nephrectomy with vena cava thrombectomy: a retrospective cohort study

 

Non-myocardial injury (n = 89)

Myocardial injury (n = 54)

P value

Non-AKI (n = 82)

AKI (n = 61)

P value

Age, year

59 (50, 67)

55 (48, 64)

0.092

56 (44, 68)

58 (46, 70)

0.433

Body mass index, kg/m2

24.2 (22.6, 27.1)

23.9 (21.6, 26.8)

0.441

24.0 (20.7, 27.3)

25.9 (19.6, 32.2)

0.021

Male sex

71 (79.8%)

34 (63.0%)

0.027

63 (76.8%)

42 (68.9%)

0.286

Comorbidities

 Stroke

3 (3.4%)

4 (7.4%)

0.278

2 (2.4%)

5 (8.2%)

0.115

 Hypertension

36 (40.4%)

22 (40.7%)

0.973

31 (37.8%)

27 (44.3%)

0.437

 Chronic heart disease a

6 (6.7%)

6 (11.1%)

0.361

6 (7.3%)

6 (9.8%)

0.591

 Diabetes Mellitus

16 (18.0%)

9 (16.7%)

0.841

17 (20.7%)

8 (13.1%)

0.236

 COPD

4 (4.5%)

0 (0.0%)

0.290

4 (4.9%)

0 (0.0%)

0.216

 Elevated transaminase b

6 (6.7%)

5 (9.3%)

0.584

7 (8.5%)

4 (6.6%)

0.660

 Abnormal kidney function c

9 (10.1%)

2 (3.7%)

0.163

8 (9.8%)

3 (4.9%)

0.283

Smoking history

29 (32.6%)

18 (33.3%)

0.926

25 (30.5%)

22 (36.1)

0.482

Previous surgery

15 (16.9%)

10 (18.5%)

0.799

18 (22.0%)

7 (11.5%)

0.103

Charlson Comorbidity Index d

2 (2, 2)

2 (2, 2)

0.748

2 (2, 2)

2 (2, 2)

0.931

Laboratory tests

 Hemoglobin, g/L

119 (105, 135)

110 (98, 130)

0.429

112 (96, 134)

117 (108, 131)

0.327

 Albumin, g/L

37.8 (35.1, 41.2)

36.5 (33.8, 40.7)

0.227

37.6 (35.1, 41.4)

37.6 (34.4, 40.8)

0.728

 cTnI, ng/ml

0.004 (0.001, 0.010) [63]

0.010 (0.007, 0.010) [27]

0.026

0.010 (0.003, 0.010) [56]

0.007 (0.001, 0.010) [34]

0.296

 cTnI > 0.03 ng/ml e

2 (2.2%)

2 (3.7%)

> 0.999

2 (2.4%)

2 (3.3%)

0.969

 Creatinine, μmol/L

96.0 (80.3, 114.0)

90.5 (80.1, 105.3)

0.422

101.0 (83.0, 117.0)

88.3 (74.2, 104.0)

0.004

ASA classification

  

0.095

  

0.732

 I

8 (9.0%)

1 (1.9%)

 

5 (6.1%)

4 (6.6%)

 

 II

59 (66.3%)

32 (59.3%)

 

54 (65.9%)

37 (60.7%)

 

 III

22 (24.7%)

20 (37.0%)

 

22 (26.8%)

20 (32.8%)

 

 IV

0 (0%)

1 (1.9%)

 

1 (1.2%)

0 (0%)

 

NYHA classification

  

0.407

  

0.531

 I

77 (86.5%)

47 (87.0%)

 

70 (85.4%)

54 (88.5%)

 

 II

12 (13.5%)

6 (11.1%)

 

12 (14.6%)

6 (9.8%)

 

 III

0 (0%)

1 (1.9%)

 

0 (0%)

1 (1.6%)

 

Right renal tumor (vs. left)

61 (68.5%)

42 (77.8%)

0.233

60 (73.2%)

43 (70.5%)

0.724

Maximal tumor diameter, cm

  

0.261

  

0.088

 0 to 5

8 (9.0%)

3 (5.6%)

 

6 (7.3%)

5 (8.2%)

 

 > 5 to 10

42 (47.2%)

33 (61.1%)

 

37 (45.1%)

38 (62.3%)

 

 > 10

39 (43.8%)

18 (33.3%)

 

39 (47.6%)

18 (29.5%)

 

Mayo classification f

  

< 0.001

  

0.531

 I

18 (20.2%)

4 (7.4%)

 

14 (17.1%)

8 (13.1%)

 

 II

27 (30.3%)

2 (3.7%)

 

19 (23.2%)

10 (16.4%)

 

 III

40 (44.9%)

23 (42.6%)

 

35 (42.7%)

28 (45.9%)

 

 IV

4 (4.5%)

25 (46.3%)

 

14 (17.1%)

15 (24.6%)

 

Interval from contrast-enhanced examination, day g

13 (7, 20)

13 (5, 20)

0.997

12 (4, 18)

14 (7, 24)

0.181

  1. Data are median (interquartile range) or number (%). Numbers in square brackets indicate patients with missing data. P values in bold indicate < 0.05
  2. COPD chronic obstructive pulmonary injury, cTnI cardiac troponin I, ASA American Society of Anesthesiologists, NYHA New York Heart Association
  3. a Including coronary artery disease, cardiac valve disease, or any type of arrhythmia requiring therapy
  4. b Serum aspartate aminotransferase and/or alanine aminotransferase were higher than the upper normal limit
  5. c Indicating serum creatinine ≥133 μmol/L
  6. d According to the 1987 version without age correction
  7. e Patients without preoperative cardiac troponin I results were regarded as within normal range
  8. f Level I, tumor thrombus extending into the IVC to no more than 2 cm above the renal vein; level II, thrombus extending into the IVC to more than 2 cm above renal vein but below the hepatic veins; level III, thrombus extending into the IVC to above the hepatic vein but not to the diaphragm; and level IV, thrombus extending into the supradiaphragmatic IVC or right atrium
  9. g Time interval from contrast-enhanced examination to surgery
Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us